Stroke prevention in patients with prediabetes and diabetes mellitus: New opportunities
O. D. Ostroumova, 
N. A. Shatalova,
A. I. Kochetkov,
T. V. Filippova,
I. F. Krotkov,
O. A. Milovanova
N. A. Shatalova,
A. I. Kochetkov,
T. V. Filippova,
I. F. Krotkov,
O. A. Milovanova https://doi.org/10.62751/2713-0177-2024-5-4-23
Abstract
Currently, stroke ranks second among the causes of death worldwide. Not only diabetes mellitus, but also prediabetes increase the risk of ischemic stroke, including recurrent stroke. Thus, in the management of patients with diabetes mellitus and prediabetes, an important aspect is the implementation of measures for the primary and secondary prevention of ischemic stroke. Both primary and secondary prevention of stroke in patients with metabolic disorders include lifestyle modification, control and maintenance of blood pressure and low-density lipoprotein cholesterol, and blood glucose control. In patients with diabetes mellitus and prediabetes, pioglitazone, a hypoglycemic drug of the thiazolidinedione group, in addition to a statistically significant decrease in blood glucose levels, reduces the risk of primary and recurrent ischemic stroke.
About the Authors
O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education;
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga D. Ostroumova – D. Sci. (Med.), Prof.
Moscow
N. A. Shatalova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Natalya A. Shatalova – Assistant
Moscow
A. I. Kochetkov
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Alexey I. Kochetkov – C. Sci. (Med.), Ass. Prof.
Moscow
T. V. Filippova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Tatiana V. Filippova – Assistant
Moscow
I. F. Krotkov
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Irina F. Krotkova – C. Sci. (Med.), Ass. Prof.
Moscow
O. A. Milovanova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Olga A. Milovanova – D. Sci. (Med.), Prof.
Moscow
References
1. Martin SS, Aday AW, Almarzooq ZI et al. 2024 heart disease and stroke statistics: A report of US and global data from the American Heart Association. Circulation. 2024; 149(8): e347–e913. doi: 10.1161/CIR.0000000000001209.
2. Игнатьева В.И., Вознюк И.А., Шамалов Н.А. с соавт. Социально-экономическое бремя инсульта в Российской Федерации. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123(8–2): 5–15. doi: 10.17116/jnevro20231230825.
3. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. 2017; 120(3): 472–95. doi: 10.1161/CIRCRESAHA.116.308398.
4. Mitsios JP, Ekinci EI, Mitsios GP et al. Relationship between glycated hemoglobin and stroke risk: A systematic review and meta-analysis. J Am Heart Assoc. 2018; 7(11): e007858. doi: 10.1161/JAHA.117.007858.
5. Cai X, Zhang Y, Li M et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: Updated meta-analysis. BMJ. 2020; 370: m2297. doi: 10.1136/bmj.m2297.
6. Janghorbani M, Hu FB, Willett WC et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: The Nurses' Health Study. Diabetes Care. 2007; 30(7): 1730–35. doi: 10.2337/dc06-2363.
7. Eriksson M, Carlberg B, Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: The Northern Sweden MONICA study. Cerebrovasc Dis. 2012; 34(2): 153–60. doi: 10.1159/000339763.
8. Desilles JP, Meseguer E, Labreuche J et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: A registry and systematic review. Stroke. 2013; 44(7): 1915–23. doi: 10.1161/STROKEAHA.111.000813.
9. Wu S, Wang C, Jia Q et al. HbA1c is associated with increased all-cause mortality in the first year after acute ischemic stroke. Neurol Res. 2014; 36(5): 444–52. doi: 10.1179/1743132814Y.0000000355.
10. Dubsky M, Veleba J, Sojakova D et al. Endothelial dysfunction in diabetes mellitus: New insights. Int J Mol Sci. 2023; 24(13): 10705. doi: 10.3390/ijms241310705.
11. Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: A focus on subjects at risk for type 2 diabetes. Curr Diab Rep. 2004; 4(4): 237–46. doi: 10.1007/s11892-004-0074-9.
12. Sumpio BE, Riley JT, Dardik A. Cells in focus: Endothelial cell. Int J Biochem Cell Biol. 2002; 34(12): 1508–12. doi: 10.1016/s1357-2725(02)00075-4.
13. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction – a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013; 1832(12): 2216–31. doi: 10.1016/j.bbadis.2013.08.006.
14. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006; 291(3): H985– 1002. doi: 10.1152/ajpheart.00292.2006.
15. Попыхова Э.Б., Степанова Т.В., Лагутина Д.Д. с соавт. Роль сахарного диабета в возникновении и развитии эндотелиальной дисфункции. Проблемы эндокринологии. 2020; 66(1): 47–55. doi: 10.14341/probl12212.
16. Степанова Т.В., Иванов А.Н., Терешкина Н.Е. с соавт. Маркеры эндотелиальной дисфункции: патогенетическая роль и диагностическое значение (обзор литературы). Клиническая лабораторная диагностика. 2019; 64(1): 34−41. doi: 10.18821/0869-2084-2019-64-1-34-41.
17. Занозина О.В., Боровков Н.Н., Щербатюк Т.Г. Свободно-радикальное окисление при сахарном диабете 2-го типа: источники образования, составляющие, патогенетические механизмы токсичности. Современные технологии в медицине. 2010; (3): 104−112.
18. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and sp1 transcriptional activation through protein kinase С-beta I and -delta. J BiolChem. 2002; 277(37): 33833–41. doi: 10.1074/jbc.M112331200.
19. Заводник И.Б., Дремза И.К., Лапшина Е.А., Чещевик В.Т. Сахарный диабет: метаболические эффекты и окислительный стресс. Биологические мембраны. 2011; 28(2): 83–94.
20. Natali A, Taddei S, Quiñones GA et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation. 1997; 96(3): 849–55. doi: 10.1161/01.cir.96.3.849.
21. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113(15): 1888–904. doi: 10.1161/CIRCULATIONAHA.105.563213.
22. Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000; 49(11): 1939–45. doi: 10.2337/diabetes.49.11.1939.
23. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24(6): 998–1005. doi: 10.1161/01.ATV.0000125114.88079.96.
24. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17(1): 121. doi: 10.1186/s12933-018-0763-3.
25. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020; 75(15): 1804–18. doi: 10.1016/j.jacc.2019.12.072.
26. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149–218. doi: 10.15829/1560-4071-2020-3-3786.
27. McEvoy JW, McCarthy CP, Bruno RM et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 30: ehae178. doi: 10.1093/eurheartj/ehae178.
28. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: Observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation. 2011; 123(24): 2799–810. doi: 10.1161/CIRCULATIONAHA.110.016337.
29. Mancia G, Kreutz R, Brunstrom M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874–2071. doi: 10.1097/HJH.0000000000003480.
30. Фонякин А. В., Гераскина Л. А. Профилактика ишемического инсульта. Рекомендации по гиполипидемической терапии. М.: ИМА-пресс. 2015; 72 с.
31. Ежов М.В., Кухарчук В.В., Сергиенко И.В. с соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 250–297. doi: 10.15829/1560-4071-2023-5471.
32. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439–54. doi: 10.1093/eurheartj/ehab309.
33. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2- OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42(25): 2455–67. doi: 10.1093/eurheartj/ehab312.
34. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023; 44(28): 2544–56. doi 10.1093/eurheartj/ehad260.
35. Nuha AE, Grazia A, Vanita R et al. Cardiovascular disease and risk management: Standards of care in diabetes—2023. Diabetes Care. 2023; 46 (Supplement_1): S158–90. doi: 10.2337/dc23-S010.
36. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23(2S): 4–102. doi: 10.14341/DM12507.
37. Kim JS, Lee G, Park KI, Oh SW. Comparative effect of glucose-lowering drugs for type 2 diabetes mellitus on stroke prevention: A systematic review and network meta-analysis. Diabetes Metab J. 2024; 48(2): 312–20. doi: 10.4093/dmj.2022.0421.
38. Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diab Rep. 2019; 19(12): 151. doi: 10.1007/s11892-019-1270-y.
39. Ионова Ж.И., Сергеева Е.Г., Беркович О.А. с соавт. Роль рецепторов активатора пролиферации пероксисом-альфа и гамма-2 в первичной и вторичной профилактике атеросклероза. Ученые записки Первого Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова. 2016; 23(2): 15–20. doi: 10.24884/1607-4181-2016-23-2-15-20.
40. Ha J, Choi DW, Kim KY et al. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: A nationwide nested case-control study. Cardiovasc Diabetol. 2021; 20(1): 152. doi: 10.1186/s12933-021-01339-x.
41. Liao HW, Saver JL, Wu YL et al Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis. BMJ Open. 2017; 7(1): e013927. doi: 10.1136/bmjopen-2016-013927.
42. Kernan WN, Viscoli CM, Dearborn JL et al. Targeting pioglitazone hydrochloride therapy after stroke or transient ischemic attack according to pretreatment risk for stroke or myocardial infarction. JAMA Neurol. 2017; 74(11): 1319–27. doi: 10.1001/jamaneurol.2017.2136.
43. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38(3): 865–73. doi: 10.1161/01.STR.0000257974.06317.49.
44. Lee M, Saver JL, Liao HW et al. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke. 2017; 48(2): 388–93. doi: 10.1161/STROKEAHA.116.013977.
Review
For citations:
Ostroumova O.D., Shatalova N.A., Kochetkov A.I., Filippova T.V., Krotkov I.F., Milovanova O.A. Stroke prevention in patients with prediabetes and diabetes mellitus: New opportunities. FOCUS. Endocrinology. 2024;5(4):88-95. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-4-23
Views:
108
Email this article 